120

Novruzova M., Talibova J., Gasimova M., Muradova S., Suleymanova T. – GENE THERAPY IN MUCOVISCIDOSIS

GENE THERAPY IN MUCOVISCIDOSIS

Novruzova M.
Doctor of Philosophy in Biology, associate professor

Talibova J.
Doctor of Philosophy in Medicine, senior lecturer

Gasimova M.
assistant

Muradova S.
Doctor of Philosophy in Biology, senior lecturer

Suleymanova T.
Doctor of Philosophy in Biology, senior lecturer
Department of Medical Microbiology and Immunology, Azerbaijan Medical University
Azerbaijan, Baku

Abstract
The article describes the advantage of the CRISPR-Cas 9 gene editing method for the treatment of cystic fibrosis. This method uses plasmids that contain CRISPR-Cas 9 components in the form of DNA, a nuclease expression cassette, and a bay RNA cassette. The advantage of the method is that no matter how CRISPR-Cas 9 is delivered to the cell, it immediately removes some gene fragment or replaces it. And this change remains forever in the cell, and in the descendant of this cell, we hope that this method of treatment will reduce the number of deaths in cystic fibrosis.

Keywords: cystic fibrosis, CRISPR-CAS-9, gene fragment, cell, mitochondria.